BIOGEN INC.
BIIBAPI behind this page
BIIB Q3 2025 request
Playground key active
/api/financials?ticker=BIIB&year=2025&quarter=3
Pick an endpoint and run the request.Income Statement
| Metric | Q3 2025 | Q3 2024 | YoY |
|---|---|---|---|
| Revenue | 2,534.7 | 2,465.8 | +2.8% |
Show Product Lines breakouts |
|||
| Alzheimer's Collaboration | 42.7 | 18.6 | +129.6% |
| Alzheimer's collaboration revenue | 42.7 | 18.6 | +129.6% |
| AVONEX | 188.5 | 176.2 | +7.0% |
| AVONEX · Non Us | 55.1 | 60.6 | -9.1% |
| AVONEX · US | 133.4 | 115.6 | +15.4% |
| BENEPALI | 121.9 | 118.1 | +3.2% |
| BENEPALI · Non Us | 121.9 | 118.1 | +3.2% |
| Biosimilars | 196.8 | 196.6 | +0.1% |
| Biosimilars · Non Us | 194.8 | 192.3 | +1.3% |
| Biosimilars · US | 2 | 4.3 | -53.5% |
| BYOOVIZ | 7 | 8 | -12.5% |
| BYOOVIZ · Non Us | 5 | 3.9 | +28.2% |
| BYOOVIZ · US | 2 | 4.1 | -51.2% |
| Contract manufacturing revenue | 141.5 | 221.9 | -36.2% |
| FLIXABI | 15.3 | 16.2 | -5.6% |
| FLIXABI · Non Us | 15.3 | 16.2 | -5.6% |
| Fumarate | 382.8 | 390.9 | -2.1% |
| Fumarate · Non Us | 148.6 | 215.9 | -31.2% |
| Fumarate · US | 234.2 | 175 | +33.8% |
| IMRALDI | 52.6 | 54.1 | -2.8% |
| IMRALDI · Non Us | 52.6 | 54.1 | -2.8% |
| Interferon | 246.9 | 237.5 | +4.0% |
| Interferon · Non Us | 85.7 | 94 | -8.8% |
| Interferon · US | 161.2 | 143.5 | +12.3% |
| MS Product Revenues | 1,061.5 | 1,053.9 | +0.7% |
| MS Product Revenues · Non Us | 418.6 | 507.9 | -17.6% |
| MS Product Revenues · US | 642.9 | 546 | +17.7% |
| Other | 55.3 | 24.1 | +129.5% |
| Other · US | 55.3 | 22.3 | +148.0% |
| PLEGRIDY | 58.4 | 61.3 | -4.7% |
| PLEGRIDY · Non Us | 30.6 | 33.4 | -8.4% |
| PLEGRIDY · US | 27.8 | 27.9 | -0.4% |
| Product | 1,846.9 | 1,769.4 | +4.4% |
| Product And Service Other | 151.2 | 231.6 | -34.7% |
| Product · Non Us | 911.6 | 956.4 | -4.7% |
| Product · US | 935.3 | 813 | +15.0% |
| QALSODY | 26.4 | 11.1 | +137.8% |
| QALSODY · Non Us | 19.1 | 5.6 | +241.1% |
| QALSODY · US | 7.3 | 5.5 | +32.7% |
| Rare Disease Product Revenue | 533.3 | 494.8 | +7.8% |
| Rare Disease Product Revenue · Non Us | 298.2 | 254.4 | +17.2% |
| Rare Disease Product Revenue · US | 235.1 | 240.4 | -2.2% |
| Revenue from anti-CD20 therapeutic programs | 493.9 | 446.2 | +10.7% |
| Royalty | 9.7 | 9.7 | 0.0% |
| Royalty Attributed To OCREVUS | 386.4 | 346.8 | +11.4% |
| SKYCLARYS | 132.9 | 102.3 | +29.9% |
| SKYCLARYS · Non Us | 58.3 | 20.5 | +184.4% |
| SKYCLARYS · US | 74.6 | 81.8 | -8.8% |
| SPINRAZA | 374 | 381.4 | -1.9% |
| SPINRAZA · Non Us | 220.8 | 228.3 | -3.3% |
| SPINRAZA · US | 153.2 | 153.1 | +0.1% |
| TECFIDERA | 168.2 | 232.8 | -27.7% |
| TECFIDERA · Non Us | 123.6 | 192.7 | -35.9% |
| TECFIDERA · US | 44.6 | 40.1 | +11.2% |
| TYSABRI | 431.8 | 406.1 | +6.3% |
| TYSABRI · Non Us | 184.3 | 178.6 | +3.2% |
| TYSABRI · US | 247.5 | 227.5 | +8.8% |
| VUMERITY | 214.6 | 158.1 | +35.7% |
| VUMERITY · Non Us | 25 | 23.2 | +7.8% |
| VUMERITY · US | 189.6 | 134.9 | +40.5% |
| ZURZUVAE | 55.3 | 22 | +151.4% |
| ZURZUVAE · US | 55.3 | 22 | +151.4% |
Show Business Segments breakouts |
|||
| Reportable Segment | 2,534.7 | 2,465.8 | +2.8% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent · Reclassification Out Of Accumulated Other Comprehensive Income | -29.1 | -7.6 | -282.9% |
| Cost of Revenue | 674.4 | 638.7 | +5.6% |
Show Product Lines breakouts |
|||
| Product · Reportable Segment | 384 | 468.2 | -18.0% |
| Royalty · Reportable Segment | 290.4 | 170.5 | +70.3% |
| Research And Development Expense Excluding Acquired In Process Cost | 436.1 | 516.2 | -15.5% |
Show Business Segments breakouts |
|||
| Reportable Segment · Early stage programs | 59.9 | 64.1 | -6.6% |
| Reportable Segment · Late stage programs | 60.4 | 56.3 | +7.3% |
| Reportable Segment · Marketed products | 107.7 | 126 | -14.5% |
| Reportable Segment · Research and discovery | 41 | 48.3 | -15.1% |
| Reportable Segment · Service Other | 167.1 | 221.5 | -24.6% |
| Research And Development Expense Including Acquired In Process Cost | 2.1 | 26.5 | -92.1% |
| Selling, General & Administrative | 594.8 | 588.4 | +1.1% |
| Amortization And Impairment Of Acquired Intangible Assets | 135.7 | 130.3 | +4.1% |
| Collaborationprofitlosssharing | 87.2 | 69.3 | +25.8% |
Show Schedule Of Equity Method Investment Equity Method Investee Name breakouts |
|||
| Samsung Bioepis | 66.5 | 60.3 | +10.3% |
Show Type Of Arrangement breakouts |
|||
| Sage Therapeutics | 20.7 | 9 | +130.0% |
| Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | 5.6 | 23.8 | -76.5% |
| Restructuring Charges | 7.4 | 6.8 | +8.8% |
Show Income Statement Location breakouts |
|||
| Research And Development Expense · 2023 Cost Saving Initiatives | 0.5 | 3.5 | -85.7% |
| Research And Development Expense · Reata Integration | 3.8 | 2.9 | +31.0% |
| Restructuring Charges · 2023 Cost Saving Initiatives | 7.4 | 4.6 | +60.9% |
| Selling General And Administrative Expenses · 2023 Cost Saving Initiatives | 0.4 | 9.1 | -95.6% |
| Selling General And Administrative Expenses · Reata Integration | 1.6 | 1.6 | 0.0% |
Show Restructuring Cost And Reserve breakouts |
|||
| Employee Severance · 2023 and 2022 Cost Saving Initiatives | 7.4 | 6.8 | +8.8% |
Show Restructuring Plan breakouts |
|||
| 2023 Cost Saving Initiatives | 8.3 | 17.2 | -51.7% |
| Reata Integration | 5.4 | 5.2 | +3.8% |
| Other Operating Income Expense Net | 34.1 | 14.8 | +130.4% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent · Reclassification Out Of Accumulated Other Comprehensive Income | 0.1 | 0.1 | 0.0% |
| Total Costs & Expenses | 1,977.4 | 2,014.8 | -1.9% |
| Income Before Taxes | 557.3 | 451 | +23.6% |
| Income Tax Expense (Benefit) | 90.8 | 62.5 | +45.3% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent · Reclassification Out Of Accumulated Other Comprehensive Income | 2.3 | 1.1 | +109.1% |
| Net Income | 466.5 | 388.5 | +20.1% |
Show Business Segments breakouts |
|||
| Reportable Segment | 466.5 | 388.5 | +20.1% |
Show Reclassification Out Of Accumulated Other Comprehensive Income breakouts |
|||
| Reclassification Out Of Accumulated Other Comprehensive Income | -20.2 | -8.1 | -149.4% |
| EPS (Basic) | 3.18 | 2.67 | +19.1% |
| EPS (Diluted) | 3.17 | 2.66 | +19.2% |
| Wtd Avg Shares (Basic) | 146.6 | 145.7 | +0.6% |
| Wtd Avg Shares (Diluted) | 147.1 | 146.1 | +0.7% |
| Operating Expenses (Q) | — | — | — |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent · Reclassification Out Of Accumulated Other Comprehensive Income | 6.7 | -1.5 | +546.7% |
| Interest Income | -31.6 | -11.6 | -172.4% |
| Other Non-Operating Income (Expense) | -15.8 | 0.8 | -2075.0% |
| Comprehensive Income | 489.8 | 388.8 | +26.0% |
| Other Comprehensive Income | 23.3 | 0.3 | +7666.7% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent | 26.5 | -41 | +164.6% |
| Accumulated Translation Adjustment | -3.2 | 41 | -107.8% |
| Foreign Currency Transaction Gain Loss Before Tax | 10.3 | 4.9 | +110.2% |
| Interest Expense | 67.4 | 59.8 | +12.7% |
Balance Sheet
| Metric | Q3 2025 | Q3 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 3,862.8 | 1,699.2 | +127.3% |
| Available For Sale Securities Debt Securities Current | 97.6 | — | — |
| Accounts Receivable (Q) | — | — | — |
Show Related Party Transactions By Related Party breakouts |
|||
| Nonrelated Party | 1,374.1 | 1,536.2 | -10.6% |
| Related Party | 475.9 | 451.9 | +5.3% |
| Inventory | 2,209.4 | 2,469.2 | -10.5% |
| Other Assets Current | 916.8 | 674 | +36.0% |
| Total Current Assets | 8,936.6 | 6,830.5 | +30.8% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 3,075.7 | — | — |
| Operating Lease Right-of-Use Assets | 330.5 | 380.4 | -13.1% |
| Goodwill | 6,490.7 | 6,485.8 | +0.1% |
| Deferred Tax Assets | 312.4 | 968.7 | -67.8% |
| Other Non-Current Assets | 729.7 | 631.4 | +15.6% |
| Total Assets | 29,207.5 | 28,313.2 | +3.2% |
| Intangible Assets | 7,528.5 | 7,958.6 | -5.4% |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 9,331.9 | 9,805.5 | -4.8% |
| Current Liabilities | |||
| Taxes Payable Current | 103.3 | 499.1 | -79.3% |
| Accounts Payable | 413.1 | — | — |
| Other Liabilities Current | 2,773.6 | — | — |
| Total Current Liabilities | 3,290 | 5,425 | -39.4% |
| Non-Current Liabilities | |||
| Long-Term Debt | 6,285.1 | 4,545.8 | +38.3% |
| Deferred Tax Liabilities | 358.1 | 882.4 | -59.4% |
| Operating Lease Liabilities | 305 | 357 | -14.6% |
| Other Non-Current Liabilities | 761.8 | — | — |
| Total Liabilities | 11,000 | 11,954.3 | -8.0% |
| Accrued Income Taxes Noncurrent | 164.7 | — | — |
| Stockholders' Equity | |||
| Common Stock | 0.1 | 0.1 | 0.0% |
| Additional Paid-In Capital | 797.7 | 488.5 | +63.3% |
| Accumulated Other Comprehensive Income | -214.8 | — | — |
| Retained Earnings | 20,601.6 | 18,993.1 | +8.5% |
| Treasury Stock Value | -2,977.1 | -2,977.1 | 0.0% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 18,207.5 | 16,358.9 | +11.3% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -214.8 | -145.7 | -47.4% |
| Additional Paid In Capital | 797.7 | 488.5 | +63.3% |
| Common Stock | 0.1 | 0.1 | 0.0% |
| Retained Earnings | 20,601.6 | 18,993.1 | +8.5% |
| Treasury Stock Common | -2,977.1 | -2,977.1 | 0.0% |
| Total Liabilities & Equity | 29,207.5 | 28,313.2 | +3.2% |
| Total Stockholders' Equity (Q) | — | — | — |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | -15.6 | -2.4 | -550.0% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | -85.5 | -31.2 | -174.0% |
| Accumulated Other Comprehensive Income | -214.8 | -145.7 | -47.4% |
| Accumulated Translation Adjustment | -113.7 | -112.1 | -1.4% |
Cash Flow Statement
| Metric | YTD Q3 2025 | YTD Q3 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Net Income | 1,341.8 | 1,365.5 | -1.7% |
Show Equity Components breakouts |
|||
| Retained Earnings | 1,341.8 | 1,365.5 | -1.7% |
Show Business Acquisition breakouts |
|||
| Reata Pharmaceuticals, Inc · Fair Value Adjustment To Inventory | 165.4 | 185.1 | -10.6% |
| Depreciation & Amortization | 579.7 | 489.2 | +18.5% |
| Impairment Of Intangible Assets Indefinitelived Excluding Goodwill | 3.5 | 20.2 | -82.7% |
| Inventory Write Down | 13.9 | 68.7 | -79.8% |
| Amortization Of Inventory Step Up | 165.4 | 185.1 | -10.6% |
| Stock-Based Compensation | 231.2 | 216.1 | +7.0% |
| Deferred Income Taxes | 194.7 | -99.7 | +295.3% |
| Increase Decrease In Equity Securities Fv Ni | 33.7 | 22.7 | +48.5% |
| Other Non-Cash Items | 49.3 | 95.1 | -48.2% |
| Change in Accounts Receivable (YTD) | — | — | — |
Show Related Party Transactions By Related Party breakouts |
|||
| Nonrelated Party | 74.9 | 127.6 | -41.3% |
| Related Party | -11.8 | -15.9 | +25.8% |
| Change in Inventory | -35.3 | -207.4 | +83.0% |
| Increase Decrease In Accrued Liabilities | -32.7 | -84.2 | +61.2% |
| Increase Decrease In Accrued Income Taxes Payable | -764.1 | 62.1 | -1330.4% |
| Increase Decrease In Other Operating Capital Net | -179.9 | -65.7 | -173.8% |
| Net Cash from Operations | 1,692.7 | 2,114.6 | -20.0% |
| Investing Activities | |||
| Capital Expenditures | -109.9 | -114.4 | +3.9% |
| Purchases of Investments | -91 | — | — |
| Payments To Acquire Intangible Assets | -15.3 | -179.1 | +91.5% |
| Proceeds From Sale Of Other Investments | 56.6 | 96.7 | -41.5% |
| Other Investing Activities | 20.2 | -4.4 | +559.1% |
| Net Cash from Investing | -139.4 | -780.6 | +82.1% |
| Financing Activities | |||
| Tax Withholding for Share Compensation | -13 | -34.8 | +62.6% |
| Proceeds From Issuance Of Long Term Debt | 1,733.1 | — | — |
| Repayments Of Long Term Debt | -1,750 | -650 | -169.2% |
| Payment For Contingent Consideration Liability Financing Activities | -141.3 | — | — |
| Proceeds From Payments For Other Financing Activities | 6.3 | -6.6 | +195.5% |
| Net Cash from Financing | -164.9 | -691.4 | +76.1% |
| Other Cash Flow | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | 1,388.4 | 642.6 | +116.1% |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 99.4 | 6.7 | +1383.6% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.